Evommune, Inc. (EVMN)

NYQ – Цена в реальном времени. Валюта: USD

25.18

+1.05 (4.35%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

25.17

-0.01 (-0.04%)

После закрытия: Jun 26, 2026, 6:40 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Evommune, Inc. (EVMN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Evommune, Inc. (EVMN)

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Видео

No Data

Пресс-релизы

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Search stocks

Evommune, Inc. (EVMN)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Evommune, Inc. (EVMN)

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Видео

No Data

Пресс-релизы

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement